Grade: Research grade

Factory Location: Hangzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe, Australasia,Asia,Middle East,Africa

Monthly Production Capacity: hundreds of grams

Packaging Information: 500mg,1g, 10g,50g 100g per package with icebag

Delivery Lead Time: In stock or 2-3 weeks

Sample Provided: yes

Payment Terms: T/T

ATX-GD-59, as a pharmaceutical peptide, is a peptide-based therapy (peptide therapy). The main biological mechanism is to imitate epitopes to inactivate leukocytes that attack the thyroid, and prevent anti-thyroid stimulating hormone receptor (TSHR) stimulating antibodies. The immunological basis that can target Graves' disease is expected to become the first modified and innovative therapy for Graves' disease in 60 years. Clinically, ATX-GD-59 has good safety and tolerability in the treatment of Graves' disease, and it can even have normal thyroid stimulating hormone receptor (TSHR) antibody levels.